44 completed, 12 terminated, 10 unknown, 3 active not recruiting. 36 Phase 3, 35 Phase 2, 2 Not applicable, 2 Phase 1, 2 Phase 4.
Follow Best Supportive Care: new trials by email Literature Review of Best Supportive Care trials Research Report on Best Supportive Care
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma Best Supportive Care, Balstilimab, Botensilimab - Colorectal Cancer | Phase 3 | Terminated | Canadian Cancer Trials Group | 21 | 2026-03-31 | 2026-07-16 |
| A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer Docetaxel for Injection (Albumin bound), Placebo, Best supportive care - Advanced Pancreatic Cancer | Phase 3 | Not yet recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 142 | 2024-08-12 | 2024-07-09 |
| Prognostic Factors for Survival in Patients With Cholangiocarcinoma Resection/Ablation of tumor, Palliative chemotherapy, Neoadjuvant chemotherapy - Cholangiocarcinoma | Unknown | Copenhagen University Hospital, Rigshospitalet | 2000 | 2024-02-01 | 2024-04-17 | |
| A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC AAA617, AAA517, Piflufolastat F 18 - Prostatic Neoplasm | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 49 | 2024-01-03 | 2026-10-21 |
| Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal Cancer Tislelizumab + Capecitabine, Best supportive care - Metastatic Colorectal Cancer，NED | Phase 2 | Recruiting | Yanhong Deng | 52 | 2023-08-22 | 2023-12-12 |
| Transanal Irrigation - Best Treatment Possibility for Low Anterior Resection Syndrome? Multicenter, Randomized Clinical Trial Transanal irrigation, Best supportive care - Low Anterior Resection Syndrome | Not applicable | Unknown | National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos | 40 | 2023-06-18 | 2023-11-08 |
| A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer [177Lu]Lu-PSMA-617, ARDT, [68Ga]Ga-PSMA-11 - Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 63 | 2023-05-05 | 2026-03-23 |
| The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302) Re-resection, Temozolomide, Lomustine - Glioblastoma, Glioblastoma Multiforme | Recruiting | Jasper Gerritsen | 464 | 2023-01-01 | 2024-02-28 | |
| The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203) Palliative Care, Tumor biopsy, Tumor resection - Glioblastoma, Glioblastoma Multiforme | Recruiting | Jasper Gerritsen | 1015 | 2023-01-01 | 2023-11-27 | |
| Masitinib for the Treatment of Severe Mast Cell Activation Syndrome Masitinib 4.5 mg/kg/day, Placebo, Best supportive care - Mast Cell Activation Syndrome | Phase 2 | Unknown | AB Science | 72 | 2022-07-01 | 2023-02-06 |
| Biliary Drainage Plus HAIC in Locally Advanced pCCA oxaliplatin and 5-fluorouracil, Biliary Drainage, Best Supportive Care - Perihilar Cholangiocarcinoma | Phase 2 | Completed | Peking University | 127 | 2021-11-01 | 2025-12-18 |
| Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger Ravulizumab, Placebo, Best Supportive Care - Thrombotic Microangiopathy | Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 16 | 2021-06-29 | 2024-10-01 |
| The Best Care for Abdominal Emergencies Study Laparotomy or laparoscopy - Acute Abdomen, Bowel Obstruction | Completed | Portsmouth Hospitals NHS Trust | 2500 | 2021-01-08 | 2025-12-26 | |
| Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant Ravulizumab, Placebo, Best supportive care - Thrombotic Microangiopathy | Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 148 | 2020-12-10 | 2026-06-18 |
| Study of Ravulizumab in Pediatric Participants With HSCT-TMA Ravulizumab, Best Supportive Care - Thrombotic Microangiopathy | Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 41 | 2020-12-07 | 2026-01-12 |
| Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection Convalescent Plasma, Best Supportive Care - COVID-19 | Phase 2 | Terminated | Hackensack Meridian Health | 21 | 2020-11-06 | 2023-10-10 |
| Convalescent Plasma for Severe COVID-19 Patients Convalescent Plasma, Best Supportive Care - Covid19 | Phase 3 | Completed | Hospital de Clinicas de Porto Alegre | 160 | 2020-07-16 | 2021-02-09 |
| Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment Masitinib, Placebo, Best Supportive Care - Indolent Systemic Mastocytosis | Phase 3 | Unknown | AB Science | 140 | 2020-07-01 | 2023-05-06 |
| Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19 Masitinib, Isoquercetin, Best Supportive Care - SARS-CoV 2, COVID-19 | Phase 2 | Unknown | AB Science | 200 | 2020-06-01 | 2023-02-06 |
| Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia IFX-1 + BSC, BSC, IFX-1 + SOC - Severe COVID-19 Pneumonia | Phase 2 / Phase 3 | Completed | InflaRx GmbH | 399 | 2020-03-31 | 2023-06-05 |
Showing 20 of 75. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (9) · Carcinoma, Hepatocellular (8) · Colorectal Neoplasms (7) · Neoplasm Metastasis (5) · Neoplasms (5) · COVID-19 (3) · Carcinoma, Transitional Cell (3) · Liver Neoplasms (3) · Thrombotic Microangiopathies (3) · Blushing (2) · Gastrointestinal Stromal Tumors (2) · Glioblastoma (2) · Mastocytosis (2) · Mastocytosis, Systemic (2) · Piebaldism (2)
AB Science (4) · Pfizer (4) · Alexion Pharmaceuticals, Inc. (3) · Canadian Cancer Trials Group (3) · Eli Lilly and Company (3) · Amgen (2) · Bristol-Myers Squibb (2) · Centre Leon Berard (2) · Genzyme, a Sanofi Company (2) · Jasper Gerritsen (2) · Novartis Pharmaceuticals (2) · AGC Biologics S.p.A. (1) · AIO-Studien-gGmbH (1) · Ain Shams University (1) · Associazione Qol-one (1)
United States (26) · France (24) · Germany (22) · Italy (21) · Canada (18) · United Kingdom (18) · South Korea (17) · Spain (15) · Belgium (14) · China (14) · Netherlands (12) · Japan (11) · Australia (10) · Brazil (10) · Poland (10)
Jasper Gerritsen, MD PhD (2) · A Vlaar, MD, PhD (1) · AbdelRahman Elnaggar, Prof. (1) · Ahmad Tarhini, MD (1) · Alexandre P Zavascki, PhD (1) · Andrea Ardizzoni, Dr (1) · Anjali Zarkar (1) · Antonio Gasbarrini, M.D. (1) · Antonio Lambiase, MD (1)
PMID 36048877, PMID 18316791, PMID 19767093, PMID 20211022, PMID 21377930, PMID 21948693, PMID 22266043, PMID 22336221, PMID 22341744, PMID 22421192, PMID 22992303, PMID 23006447, PMID 23059776, PMID 23177515, PMID 23328269, PMID 23625191, PMID 23835707, PMID 23980090, PMID 24387239, PMID 24419418, PMID 24957256, PMID 25104617, PMID 25655899, PMID 25881079, PMID 26049686, PMID 26386123, PMID 26784946, PMID 27068858, PMID 27416912, PMID 28069279, PMID 28131794, PMID 28611200, PMID 29397354, PMID 29424248, PMID 29627309, PMID 30021548, PMID 31413923, PMID 31790344, PMID 32379280, PMID 32945632, PMID 33015643, PMID 33197226, PMID 34213592, PMID 34473343, PMID 34616489, PMID 34893775, PMID 34973108, PMID 35029045, PMID 35416053, PMID 35623069
2015 (4), 2009 (1), 2016 (1), 2018 (1)